Hat Trick For Xofluza As Canadian, Swiss & Australian Regulators Join Forces
Xofluza is also the first non-cancer drug to be reviewed under the Australia-Canada-Singapore-Switzerland (ACSS) Consortium’s work-sharing initiative.
You may also be interested in...
Hot on the heels of announcing it was joining Project Orbis, the UK drug regulator, the MHRA, now says it will join another international collaboration that allows drug companies to submit medicines for review by several countries at the same time.
The coronavirus outbreak shows how vulnerable vast numbers of people remain to potentially deadly viruses. Roche boss Severin Schwan believes that the lessons being learnt about COVID-19 should be applied to tackling flu.
The joint review by Australia and Canada of the metastatic breast cancer drug, Verzenio, helped regulators in both jurisdictions achieve efficiencies.